BC Innovations | Sep 15, 2016
Product R&D

Enter GammaDelta

Lauren Martz, Senior Writer  Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many...
Items per page:
1 - 1 of 1